P499. Efficacy of adalimumab for induction and maintenance of remission in intestinal Behçet's disease
A. Yamada, Y. Suzuki, T. Sasaki, M. Katsumata, M. Miyamura, K. Hirayama, N. Arai, H. Kikuchi, R. Iwasa, R. Furukawa, K. Sono, A. Osamura, K. Nakamura, H. Aoki, Y. Yoshimatsu, Y. Tsuda, K. Takeuchi, N. Takada, Toho University, Sakura Medical Centre, Division of Gastroenterology, Department of Internal Medicine, Sakura, Japan
Behçet's disease (BD) is chronic inflammatory disease affecting multiple organ systems, such as the skin, joints, blood vessels, central nervous system, and gastrointestinal tract. Intestinal BD is characterized by intestinal inflammation with round and oval ulcers associated with gastrointestinal symptoms. Gastrointestinal lesions of BD are often refractory to medical therapy. Although several cases have been reported that anti-TNF therapy, mainly infliximab, is effective for induction of remission, and maintaining remission, but a few reported about adalimumab (ADA). We reported about the efficacy of ADA for remission and maintenance therapy in intestinal BD patients.
This study was single center retrospective analysis. From August 2011 to October 2013, Seven cases (3 female and 4 male) with active intestinal BD were treated with ADA as an induction remission therapy, there after clinical corse were monitored, had colonoscopies performed up to 8 weeks after induction therapy. All paitients were steroid-dependent or refractory. The remission induction rate, the maintenance rate and the endoscopic findings were evaluated.
The remission induction rate 8 weeks after the treatment with ADA was 42.8% (3/7), and all of these patients maintained remission with scheduled treatments of ADA. The rate of improvement of endoscopic findings was 42.8% (3/7) after 8 weeks. Overall ADA achieved clinical improvement and keep remission and response in 5 of the 7 patients.
ADA appears to offer an option for active intestinal BD to induce and maintain remission.